News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
May, 2025
May 2025
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Al-Ola Abdallah: Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy
Al-Ola Abdallah/LinkedIn
May 1, 2025, 10:25

Al-Ola Abdallah: Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy

Al-Ola Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared an article by Donald Waddell, et al. on X:

“Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy.

  • TPO-RAs did not increase the rate of thrombocytopenia resolution relative to supportive care.
  • Adverse effects requiring therapy modification related to TPO-RAs occurred in 25% of patients.
  • The financial toxicity associated with TPO-RAs was roughly $87,000.”

Al-Ola Abdallah: Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy

Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy.

Authors: Donald Waddell, Jennifer Collins, Sarvnaz Sadrameli

You can Read the Full Article on Journal of Transplantation and Cellular Therapy.

Al-Ola Abdallah: Utility of Thrombopoietin Receptor Agonists for Prolonged Thrombocytopenia After Chimeric Antigen Receptor T-cell Therapy

More posts featuring Al-Ola A Abdallah.

Al-Ola A Abdallah cancer Donald Waddell fight against cancer Global fight against cancer Jennifer Collins OncoDaily Oncology Plasma Cell disorder program Sarvnaz Sadrameli T-cell therapy Thrombocytopenia Thrombopoietin TPO-RAs transplantation and cellular therapy University of Kansas Medical Center
Special Coverage
Blog
May 20, 2025, 17:22
The Lancet Group's Editorial Team Will Be on the Ground at ASCO 2025
Blog
May 20, 2025, 17:11
Pam Traxel: One in Ten Cancer Survivors Rely on Medicaid - Cuts Have Consequences
Blog
May 20, 2025, 16:58
Elvina Majiwa and Murallitharan Munisamy Have Won The World No Tobacco Day Award - UICC
Blog
May 20, 2025, 16:56
PER Tumor Board: Applying Recent Advances to Transform the Treatment Paradigm in SCLC
Blog
May 20, 2025, 16:46
Shahrin Ahmed: Specific Pre-surgery Medication Improves Survival Rates in Hereditary Breast Cancer Cases
Blog
May 20, 2025, 16:43
Ahmed Magdy Rabea: Pleased to Give a Multiple Myeloma Awareness Session to the Pfizer Egypt Team
Blog
May 20, 2025, 16:37
Sachin Jain: The Greatest Impact of AI Will Come from Improving Care and Service
Blog
May 20, 2025, 16:27
It Is Time to Invest in Cancer Research - Stand Up To Cancer
Insight
May 20, 2025, 15:50
Oliver Bogler Announced the Launch of the NanCI AI Webapp for Scientific Literature and Networking
Blog
May 20, 2025, 15:37
Fumiko Ladd Chino: Even with Superlative Healthcare You Can Still End Up with Stage 4 Cancer
Blog
May 20, 2025, 15:20
Save the date for the 7th CCI4EU Online Course - "Early Cancer Detection, Screening, and Prevention"
Insight
May 20, 2025, 15:05
New JCO Oncology Practice Piece on Debunking Myths of Hope in Cancer Care